{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:29:47Z","timestamp":1793651387331,"version":"4.5.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006775","name":"GE | GE Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006775","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Images of DaTscan (ioflupane [123I] SPECT) have been used as an adjunct to clinical diagnosis to facilitate the differential diagnosis of neurodegenerative (ND) Parkinsonian Syndrome (PS) vs. non-dopamine deficiency aetiologies of Parkinsonism. Despite several systematic reviews having summarised the evidence on diagnostic accuracy, the impact of imaging results on clinical utility has not been systematically assessed. Our objective was to examine the available evidence on the clinical utility of DaTscan imaging in changing diagnosis and subsequent management of patients with suspected PS. We performed a systematic review of published studies of clinical utility from 2000 to 2019 without language restrictions. A meta-analysis of change in diagnosis and management rates reported from each study was performed using a random-effects model and logit transformation. Sub-group analysis, meta-regression and sensitivity analysis was performed to explore heterogeneity. Twenty studies met the inclusion criteria. Thirteen of these contributed to the meta-analyses including 950 and 779 patients with a reported change in management and change in diagnosis, respectively. The use of DaTscan imaging resulted in a change in management in 54% (95% CI: 47\u201361%) of patients. Change in diagnosis occurred in 31% (95% CI: 22\u201342%) of patients. The two pooled analyses were characterised by high levels of heterogeneity. Our systematic review and meta-analysis show that imaging with DaTscan was associated with a change in management in approximately half the patients tested and the diagnosis was modified in one third. Regardless of time from symptom onset to scan results, these changes were consistent. Further research focusing on specific patient subgroups could provide additional evidence on the impact on clinical outcomes.<\/jats:p>","DOI":"10.1038\/s41531-021-00185-8","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T06:02:53Z","timestamp":1621836173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"7","author":[{"given":"Danny","family":"Bega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip H.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7519-8774","authenticated-orcid":false,"given":"Anastasia","family":"Chalkidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz T.","family":"Grzeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7274-797X","authenticated-orcid":false,"given":"Thomas","family":"Macmillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulfiqar H.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,24]]},"reference":[{"key":"185_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V","volume":"15","author":"TS Benamer","year":"2000","unstructured":"Benamer, T. S. et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov. Disord. 15, 503\u2013510 (2000).","journal-title":"Mov. Disord."},{"key":"185_CR2","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00702-004-0208-x","volume":"112","author":"M Plotkin","year":"2005","unstructured":"Plotkin, M. et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J. Neural Transm. 112, 677\u2013692 (2005).","journal-title":"J. Neural Transm."},{"key":"185_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","volume":"86","author":"G Rizzo","year":"2016","unstructured":"Rizzo, G. et al. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 86, 566\u2013576 (2016).","journal-title":"Neurology"},{"key":"185_CR4","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1093\/brain\/120.12.2187","volume":"120","author":"A Antonini","year":"1997","unstructured":"Antonini, A. et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson\u2019s disease. Brain 120, 2187\u20132195 (1997).","journal-title":"Brain"},{"key":"185_CR5","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/ene.12444","volume":"21","author":"F Brigo","year":"2014","unstructured":"Brigo, F., Matinella, A., Erro, R. & Tinazzi, M. [(1)(2)(3)I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson\u2019s disease and vascular or drug-induced parkinsonisms: a meta-analysis. Eur. J. Neurol. 21, 1369\u2013e1390 (2014).","journal-title":"Eur. J. Neurol."},{"key":"185_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000370116","volume":"15","author":"D Bega","year":"2015","unstructured":"Bega, D., Gonzalez-Latapi, P., Zadikoff, C., Spies, W. & Simuni, T. Is there a role for DAT-SPECT imaging in a specialty movement disorders practice? Neurodegener. Dis. 15, 81\u201386 (2015).","journal-title":"Neurodegener. Dis."},{"key":"185_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000337351","volume":"11","author":"A Kupsch","year":"2013","unstructured":"Kupsch, A. et al. Changes in clinical management and diagnosis following DaTscan SPECT imaging in patients with clinically uncertain parkinsonian syndromes: a 12-week follow-up study. Neurodegener. Dis. 11, 22\u201332 (2013).","journal-title":"Neurodegener. Dis."},{"key":"185_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jocn.2008.01.020","volume":"16","author":"C Bairactaris","year":"2009","unstructured":"Bairactaris, C. et al. Impact of dopamine transporter single photon emission computed tomography imaging using I-123 ioflupane on diagnoses of patients with parkinsonian syndromes. J. Clin. Neurosci. 16, 246\u2013252 (2009).","journal-title":"J. Clin. Neurosci."},{"key":"185_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/1941874419829293","volume":"9","author":"S Bhattacharjee","year":"2019","unstructured":"Bhattacharjee, S., Paramanandam, V. & Bhattacharya, A. Analysis of the effect of dopamine transporter scan on the diagnosis and management in a Tertiary Neurology Center. Neurohospitalist 9, 144\u2013150 (2019).","journal-title":"Neurohospitalist"},{"key":"185_CR10","first-page":"751","volume":"111","author":"GF Crotty","year":"2018","unstructured":"Crotty, G. F., O\u2019Corragain, O., Bogue, C., Crotty, J. & O\u2019Sullivan, S. S. The utility of dopamine transporter scans for diagnosing Parkinsonian disorders. Ir. Med. J. 111, 751 (2018).","journal-title":"Ir. Med. J."},{"key":"185_CR11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0212-6982(05)74184-7","volume":"24","author":"AM Garcia Vicente","year":"2005","unstructured":"Garcia Vicente, A. M. et al. Utility of 123-I ioflupane SPECT in the assessment of patients with parkinsonian syndrome and cerebral vasculopathy. [Spanish]. Rev. Espanola de. Med. Nucl. 24, 392\u2013403 (2005).","journal-title":"Rev. Espanola de. Med. Nucl."},{"key":"185_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000447561","volume":"17","author":"AK Graebner","year":"2017","unstructured":"Graebner, A. K. et al. Clinical impact of 123I-ioflupane SPECT (DaTscan) in a Movement Disorder Center. Neurodegener. Dis. 17, 38\u201343 (2017).","journal-title":"Neurodegener. Dis."},{"key":"185_CR13","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00702-005-0401-6","volume":"113","author":"S Hesse","year":"2006","unstructured":"Hesse, S. et al. Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. J. Neural Transm. 113, 1177\u20131190 (2006).","journal-title":"J. Neural Transm."},{"key":"185_CR14","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1001\/archneur.61.8.1224","volume":"61","author":"DL Jennings","year":"2004","unstructured":"Jennings, D. L. et al. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch. Neurol. 61, 1224\u20131229 (2004).","journal-title":"Arch. Neurol."},{"key":"185_CR15","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s00259-002-0938-7","volume":"29","author":"A Lokkegaard","year":"2002","unstructured":"Lokkegaard, A., Werdelin, L. M. & Friberg, L. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur. J. Nucl. Med. Mol. Imaging 29, 1623\u20131629 (2002).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"185_CR16","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.0000000000000424","volume":"82","author":"K Marek","year":"2014","unstructured":"Marek, K. et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 82, 1791\u20131797 (2014).","journal-title":"Neurology"},{"key":"185_CR17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/01.mnm.0000243374.11260.5b","volume":"27","author":"VL Marshall","year":"2006","unstructured":"Marshall, V. L., Patterson, J., Hadley, D. M., Grosset, K. A. & Grosset, D. G. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl. Med. Commun. 27, 933\u2013937 (2006).","journal-title":"Nucl. Med. Commun."},{"key":"185_CR18","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/RLU.0000000000002240","volume":"43","author":"S Mirpour","year":"2018","unstructured":"Mirpour, S., Turkbey, E. B., Marashdeh, W., El Khouli, R. & Subramaniam, R. M. Impact of DAT-SPECT on management of patients suspected of Parkinsonism. Clin. Nucl. Med. 43, 710\u2013714 (2018).","journal-title":"Clin. Nucl. Med."},{"key":"185_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mdc3.12261","volume":"3","author":"S Oravivattanakul","year":"2016","unstructured":"Oravivattanakul, S. et al. Dopamine transporter (DaT) scan utilization in a Movement Disorder Center. Mov. Disord. Clin. Pract. 3, 31\u201335 (2016).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"185_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.parkreldis.2014.10.022","volume":"21","author":"S Sadasivan","year":"2015","unstructured":"Sadasivan, S. & Friedman, J. H. Experience with DaTscan at a tertiary referral center. Parkinsonism Relat. Disord. 21, 42\u201345 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"185_CR21","first-page":"29","volume":"2","author":"KD Seifert","year":"2013","unstructured":"Seifert, K. D. & Wiener, J. I. The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study. Am. J. Neurodegener. Dis. 2, 29\u201334 (2013).","journal-title":"Am. J. Neurodegener. Dis."},{"key":"185_CR22","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s00415-011-6076-z","volume":"258","author":"F Sixel-Doring","year":"2011","unstructured":"Sixel-Doring, F., Liepe, K., Mollenhauer, B., Trautmann, E. & Trenkwalder, C. The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases. J. Neurol. 258, 2147\u20132154 (2011).","journal-title":"J. Neurol."},{"key":"185_CR23","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00415-014-7634-y","volume":"262","author":"C Thiriez","year":"2015","unstructured":"Thiriez, C. et al. Clinical routine use of dopamine transporter imaging in 516 consecutive patients. J. Neurol. 262, 909\u2013915 (2015).","journal-title":"J. Neurol."},{"key":"185_CR24","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/mds.20112","volume":"19","author":"E Tolosa","year":"2004","unstructured":"Tolosa, E. et al. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov. Disord. 19, 1175\u20131182 (2004).","journal-title":"Mov. Disord."},{"key":"185_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.parkreldis.2018.04.037","volume":"53","author":"J Yomtoob","year":"2018","unstructured":"Yomtoob, J., Koloms, K. & Bega, D. DAT-SPECT imaging in cases of drug-induced parkinsonism in a specialty movement disorders practice. Parkinsonism Relat. Disord. 53, 37\u201341 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"185_CR26","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.2967\/jnumed.107.043687","volume":"48","author":"BE Hillner","year":"2007","unstructured":"Hillner, B. E. et al. The National Oncologic PET Registry (NOPR): design and analysis plan. J. Nucl. Med. 48, 1901\u20131908 (2007).","journal-title":"J. Nucl. Med."},{"key":"185_CR27","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici, G. D. et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA 321, 1286\u20131294 (2019).","journal-title":"JAMA"},{"key":"185_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/WAD.0b013e318279d02a","volume":"27","author":"M Grundman","year":"2013","unstructured":"Grundman, M. et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis. Assoc. Disord. 27, 4\u201315 (2013).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"185_CR29","doi-asserted-by":"crossref","unstructured":"Antonini, A. et al. The relationship between cerebral vascular disease and parkinsonism: The VADO study, Parkinsonism & Related Disorders, 18, 775\u2013780, https:\/\/doi.org\/10.1016\/j.parkreldis.2012.03.017 (2012).","DOI":"10.1016\/j.parkreldis.2012.03.017"},{"key":"185_CR30","doi-asserted-by":"publisher","unstructured":"Miguel-Puga, A., Villafuerte, G., Salas-Pacheco, J. & Arias-Carri\u00f3n, O. Therapeutic interventions for vascular Parkinsonism: a systematic review and meta-analysis. Front. Neurol. 8, https:\/\/doi.org\/10.3389\/fneur.2017.00481 (2017).","DOI":"10.3389\/fneur.2017.00481"},{"key":"185_CR31","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"The Parkinson Study Group.","year":"2004","unstructured":"The Parkinson Study Group. Levodopa and the progression of Parkinson\u2019s disease. N. Engl. J. Med. 351, 2498\u20132508 (2004).","journal-title":"N. Engl. J. Med."},{"key":"185_CR32","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1212\/WNL.29.7.951","volume":"29","author":"CG Matthews","year":"1979","unstructured":"Matthews, C. G. & Haaland, K. Y. The effect of symptom duration on cognitive and motor perfomname in parkinsonism. Neurology 29, 951\u2013951 (1979).","journal-title":"Neurology"},{"key":"185_CR33","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/mds.21429","volume":"22","author":"A Schrag","year":"2007","unstructured":"Schrag, A. et al. Rate of clinical progression in Parkinson\u2019s disease. A prospective study. Mov. Disord. 22, 938\u2013945 (2007).","journal-title":"Mov. Disord."},{"key":"185_CR34","unstructured":"Ughreja, K. et al. In American Academy of Neurology (AAN) 70th Annual Meeting. (2018)."},{"key":"185_CR35","doi-asserted-by":"publisher","unstructured":"Borenstein, M., Hedges, L., Higgins, J. P. T. & Rothstein, H. R. Fixed-Effect Versus Random-Effects Models. Introduction To Meta-analysis 77\u201386, https:\/\/doi.org\/10.1002\/9780470743386.ch13 (Wiley, 2009).","DOI":"10.1002\/9780470743386.ch13"},{"key":"185_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials 7, 177\u2013188 (1986).","journal-title":"Control. Clin. Trials"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00185-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00185-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00185-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T16:51:55Z","timestamp":1669999915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00185-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,24]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["185"],"URL":"https:\/\/doi.org\/10.1038\/s41531-021-00185-8","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,24]]},"assertion":[{"value":"30 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: A.C., T.M. and M.G. received funding for this analysis from GE Healthcare and are employees of Kings College London. D.B., P.K. and A.A. have acted as consultants for GE Healthcare. P.K. has acted as a consultant, speaker and grant recipient for GE Healthcare and is an employee of Konica-Minolta. A.A. has received compensation for consultancy and speaker-related activities from UCB, Boehringer\u2013Ingelheim, General Electric, Britannia, AbbVie, Kyowa Kirin, Zambon, Bial, Neuroderm, Theravance Biopharma, Roche; he receives research support from Chiesi Pharmaceuticals, Bial, Lundbeck, Horizon2020 - Grant 825785, Horizon2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, Cariparo Foundation. He serves as a consultant for Boehringer\u2013Ingelheim for legal cases on pathological gambling. Z.H. and C.B. are employees of GE Healthcare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}